Analysts trimmed price targets across several sectors on Thursday. Healthcare and consumer names bore the brunt of the cuts.
ResMed saw its consensus target fall to $284.64 from $288.21. The sleep-therapy device maker carries 7.9% short interest as a percentage of free float. Bears remain active despite the stock's $30.7bn market cap.
The Clorox Company also drew a downward consensus revision. Its average target slipped to $114.88. Short interest sits at 7.4% of free float — elevated for a consumer staples name.
Willis Towers Watson took the steepest proportional target cut. The consensus dropped to $346.95 from $352.79. That is a $5.84 reduction. With short interest at just 2.2% of free float, the move looks driven by fundamentals rather than short pressure.
Stryker Corporation also faced a trim. Its target fell to $416.04. The medical devices giant has strong buy coverage — 23 buy ratings versus just one sell.
On the positive side, Apple bucked the trend. Its consensus target edged up to $298.81. and also received upward revisions. Both trade with broad analyst support and improving EPS momentum heading into May.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
